Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

cogstate
October 10th, 2023

Acquisition Targets for Australian Biotech Sector (Cogstate)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

dmx1
October 10th, 2023

Major Validation Deal for Dimerix

Dimerix (DXB: $0.16) has signed a licensing deal for its lead compound, DMX-200, with Advanz Pharma. The deal gives Advanz rights to the use of DMX-200 for the treatment of FSGS (Focal Segmental Glomerulosclerosis) in Europe, the UK, Canada, Australia and New Zealand.

AVR1
October 3rd, 2023

Acquisition Targets for Australian Biotech Sector (Anteris Technologies)

Over the next 12-24 months a number of companies in the sector may receive acquisition bids. The last company to be acquired was ResApp Health for $180 million by Pfizer in 2022. Three companies viewed as potential targets by Bioshares are discussed below.

PXS1
October 3rd, 2023

Pharmaxis (Syntara) Sells off Mannitol Business

Not surprisingly, Pharmaxis (PXS: $0.035) will sell off its mannitol drug business. The acquiror is Australian-based Arna Pharma.

 

CUV 943
September 19th, 2023

Clinuvel Pharmaceuticals v. Nanosonics

Two highly successful life science companies that have emerged in the last decade in Australia are Clinuvel Pharmaceuticals (CUV: $15.64) and Nanosonics (NAN: $4.37). Whilst one is a pharmaceutical company and the other sells medical products (the Trophon disinfection instrument for ultrasound probes), there are several commonalities between the two businesses which make a comparison worthwhile.

5abaa61354d3df5e6c0ffba7_HeroAroa
September 19th, 2023

Polynovo v AROA Biosurgery

By most measures, except for net profit, Polynovo (PNV: $1.28) has delivered an exceptionally strong year in FY2023. Revenue has increased by 59% to $66.5 million, the numbers of hospitals/customers has increased by 168 to 638, and its staff numbers have also surged by 66 to 218.

 

respiri 944
September 4th, 2023

Respiri Signs Three US Remote Patient Monitoring Contracts

Having wrapped up the acquisition of Access Managed Services, Respiri (RSH: $0.03) has quickly moved to securing new initial patient monitoring contracts.

 

 

COGSTATE 943
September 4th, 2023

Disappointing Half Year Sales for Cogstate; Pipeline for New Contracts at All-time High Levels

A robust 1H23 in recorded clinical trial sales amounting to US$27.3M was followed by a reduction of approximately 75% in 2H23, with sales totalling just US$6.7M. This marks a decline in overall clinical trial sales of 59% from the record reported in FY22 of US$82.5 million.

IMUGENE 2
September 4th, 2023

Imugene to Acquire Fourth Technology Platform

Imugene (IMU: $0.065) has announced it will acquire its fourth technology platform in cancer immunotherapy. The company is in-licensing an allogeneic CAR-T program, called Azer-Cel, from US company Precision Biosciences.

CUV 944
September 4th, 2023

Robust Growth Expected to Continue for Clinuvel Pharmaceuticals

For FY2023, Clinuvel Pharmaceuticals (CUV: $18.15) achieved total revenues of $83 million, which was up 24% on the previous year. The net profit for the year increased by 47% to $30.6 million. The company finished the year with $157 million in cash.

Pages